Skip to main content
. Author manuscript; available in PMC: 2023 Oct 31.
Published in final edited form as: Sci Transl Med. 2023 Mar 29;15(689):eade5795. doi: 10.1126/scitranslmed.ade5795

Fig. 2. Therapeutic mAb administration protects hamsters from pathogenic YFV infection.

Fig. 2.

(A) Kaplan-Meier survival curves of Syrian golden hamsters after challenge with YFV-Jimenez and treatment with YFV-specific or isotype control antibodies. P value determined by Mantel-Cox test with Bonferroni correction. (B) YFV-Jimenez titers in the sera of Syrian golden hamsters at 4 and 6 dpi as measured by an ex vivo infection assay to determine CCID50. One hamster from the MBL-YFV-01 group had insufficient serum at 6 dpi to measure YFV-Jimenez titers. P values determined by Mann-Whitney test with Bonferroni correction. Limit of quantification (LOQ), 1.67 log10. (C) Longitudinal mean weight change of each hamster treatment group after challenge with YFV-Jimenez. (D) Serum ALT levels of each hamster 6 dpi and measurements from normal controls. Two hamsters in the isotype control group and one hamster in the MBL-YFV-01 group had insufficient serum to measure ALT levels. P values determined by Mann-Whitney test with Bonferroni correction. **P < 0.01 and ***P < 0.001.